SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 191 filers reported holding SANGAMO THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $31,965 | -53.7% | 10,180 | -27.2% | 0.04% | -56.0% |
Q3 2022 | $69,000 | -5.5% | 13,980 | -21.4% | 0.08% | +2.4% |
Q2 2022 | $73,000 | -62.2% | 17,780 | -46.7% | 0.08% | -40.6% |
Q1 2022 | $193,000 | -22.8% | 33,380 | 0.0% | 0.14% | -23.3% |
Q4 2021 | $250,000 | -19.9% | 33,380 | -3.5% | 0.18% | -13.9% |
Q3 2021 | $312,000 | -25.2% | 34,580 | -0.9% | 0.21% | -33.9% |
Q2 2021 | $417,000 | -99.9% | 34,880 | +0.9% | 0.32% | -4.5% |
Q1 2021 | $388,679,000 | +66454.6% | 34,580 | -0.3% | 0.33% | -38.4% |
Q4 2020 | $584,000 | +94.7% | 34,680 | +3.3% | 0.54% | +53.4% |
Q2 2020 | $300,000 | +14.9% | 33,580 | +7.4% | 0.35% | +28.2% |
Q4 2019 | $261,000 | -0.4% | 31,280 | +7.9% | 0.27% | -10.8% |
Q3 2019 | $262,000 | -3.0% | 28,980 | +15.6% | 0.31% | -6.4% |
Q2 2019 | $270,000 | +22.7% | 25,080 | +8.7% | 0.33% | +18.5% |
Q1 2019 | $220,000 | -9.1% | 23,080 | +9.1% | 0.28% | -23.3% |
Q4 2018 | $242,000 | -24.8% | 21,150 | +11.0% | 0.36% | -2.2% |
Q3 2018 | $322,000 | – | 19,050 | – | 0.37% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Alexandria Capital, LLC | 968,505 | $12,135,000 | 1.23% |
Golden State Equity Partners | 126,608 | $1,586,000 | 0.90% |
McGuire Investment Group, LLC | 272,801 | $3,418,000 | 0.72% |
Lombard Odier Asset Management (Switzerland) SA | 848,429 | $10,631,000 | 0.70% |
Rhenman & Partners Asset Management AB | 765,000 | $9,585,000 | 0.67% |
EMC Capital Management | 72,061 | $903,000 | 0.64% |
WASATCH ADVISORS LP | 10,328,423 | $129,415,000 | 0.58% |
Ceeto Capital Group, LLC | 74,000 | $927,000 | 0.45% |
Fort Sheridan Advisors LLC | 75,945 | $952,000 | 0.38% |
Vanguard Capital Wealth Advisors | 34,580 | $388,679,000 | 0.33% |